Kite CEO plans to learn from Gilead's pricing playbook

January 15, 2015 7:16 PM

20 0

(Reuters) - Kite Pharma Inc plans to open conversations with insurers this year to lay the groundwork for an experimental cancer treatment that could cost hundreds of thousands of dollars if it works and is approved by regulators, top executives said this week.

The possible treatment has yet to start a broad clinical trial, but the urgency comes as biotech and pharma companies consider how to navigate pushback by health insurers against Gilead Sciences Inc on the price of its hepatitis C treatment.

Read more

To category page